Certain Territories Sample Clauses

Certain Territories. Schedule 1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Certain Information Relating to 1997

Certain Territories. Schedule 1 [INTENTIONALLY OMITTED -- CONFIDENTIAL TREATMENT REQUESTED] CONFIDENTIAL TREATMENT REQUESTED BY GALILEO INTERNATIONAL, INC. MARKETING COOPERATION AND SALES REPRESENTATION AGREEMENT UNITED AIR LINES, INC. AND GALILEO INTERNATIONAL, INC. This Marketing Cooperation and Sales Representation Agreement (this "Agreement") effective as of the ___ day of _______, 1997 (the "Effective Date"), by and between GALILEO INTERNATIONAL, INC., a Delaware corporation ("GI-Inc") with offices at Suit▇ ▇▇▇, ▇▇▇▇ ▇▇▇▇ ▇▇▇▇▇▇▇ ▇▇▇▇, Rosemont, Illinois, 60018, and UNITED AIR LINES, INC., a Delaware corporation ("United") with offices at 1200 ▇. ▇▇▇▇▇▇▇▇▇ ▇▇▇▇, ▇▇▇ ▇▇▇▇▇ ▇▇▇▇▇▇▇▇, ▇▇▇▇▇▇▇▇ ▇▇▇▇▇.

Certain Territories. 2.1.1 There are certain countries, namely, Belgium, Finland, Luxemburg, and The Netherlands (including the Dutch Overseas Territories), in which Sanquin has historically operated (each, a “Sanquin Precedent Country,” and, collectively, the “Sanquin Precedent Countries”). 2.1.2 There are certain countries in Europe, namely France, Ireland, and the United Kingdom, in which Sanquin currently has agreements in place with Third Parties (each, an “Existing Europe Distributor,” and, collectively, the “Existing Europe Distributors”) for the distribution of Cetor Product and/or Cetor NF Product manufactured by Sanquin (each, a “Sanquin Partnered Country (Europe),” and, collectively, the “Sanquin Partnered Countries (Europe)”). 2.1.3 There are certain countries outside of Europe, namely, Egypt, Iran, Israel (including the Palestinian Authority), Indonesia and Turkey, and the countries of North, Central, and South America (for the avoidance of doubt: excluding the Dutch Overseas Territories) in which Sanquin currently has agreements in place with Third Parties and an Affiliate of ViroPharma (each, an “Existing ROW Distributor,” and, collectively, the “Existing ROW Distributors”) for the distribution of Cinryze and Cetor product and/or Cetor NF Product, respectively, manufactured by Sanquin (each, a “Sanquin Partnered Country (ROW),” and, collectively, the “Sanquin Partnered Countries (ROW)”); provided, however, that each of the following countries: (i) all countries in North, Central and South America, excluding the Dutch Overseas Territories, Argentina and Brazil, and (ii) Israel (including the Palestinian Authority)) is only a Sanquin Partnered Country (ROW) to the extent of the ViroPharma Product as it exists on the Effective Date; with respect to any improvement of the ViroPharma Product after the Effective Date upon execution by ViroPharma of its first right of refusal as referred to in Section 3.2.4 and/or any improvement to such Product as agreed by the Parties, such countries are part of the ViroPharma Territory.